Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor

Abstract

Current antagonists for the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (PTHR) are N-terminally truncated or N-terminally modified analogs of PTH(1-34) or PTHrP(1-34) and are thought to bind predominantly to the N-terminal extracellular (N) domain of the receptor. We hypothesized that ligands that bind only to PTHR region comprised of the extracellular loops and seven transmembrane helices (the juxtamembrane or J domain) could also antagonize the PTHR. To test this, we started with the J domain-selective agonists [Gln10,Ala12,Har11,Trp 14,Arg19 (M)]PTH(1-21), [M]PTH(1-15), and [M]PTH(1-14), and introduced substitutions at positions 1-3 that were predicted to dissociate PTHR binding and cAMP signaling activities. Strong dissociation was observed with the tri-residue sequence diethylglycine (Deg)1-para-benzoyl-L- phenylalanine (Bpa)2-Deg3. In HKRK-B7 cells, which express the cloned human PTHR, [Deg1,3,Bpa2,M]PTH(1-21), [Deg1,3,Bpa2,M]PTH(1-15), and [Deg1,3,Bpa 2,M]PTH(1-14) fully inhibited (IC50s = 100-700 nM) the binding of 123I-[α-aminoisobutyric acid1,3,M]PTH(1- 15) and were severely defective for stimulating cAMP accumulation. In ROS 17/2.8 cells, which express the native rat PTHR, [Deg1,3,Bpa 2,M]PTH(1-21) and [Deg1,3,Bpa2,M]PTH(1-15) antagonized the cAMP-agonist action of PTH(1-34), as did PTHrP(5-36) (IC 50S = 0.7 μM, 2.6 nM, and 36 nM, respectively). In COS-7 cells expressing PTHR-delNt, which lacks the N domain of the receptor, [Deg 1,3,Bpa2, M]PTH(1-21) and [Deg1,3,Bpa 2,M]PTH(1-15) inhibited the agonist actions of [α- aminoisobutyric acid1,3]PTH(1-34) and [M]PTH(1-14) (IC50s -1 μM), whereas PTHrP(5-36) failed to inhibit. [Deg1,3,Bpa 2,M]PTH(1-14) inhibited the constitutive cAMP-signaling activity of PTHR-tether-PTH(1-9), in which the PTH(1-9) sequence is covalently linked to the PTHR J domain, as well as that of PTHRcamH223R. Thus, the J-domain-selective N-terminal PTH fragment analogs can function as antagonists as well as inverse agonists for the PTHR. The new ligands described should be useful for further studies of the ligand binding and activation mechanisms that operate in the critical PTHR J domain.